Stenotrophomonas maltophilia: Results of Antimicrobial Susceptibility Testing and In Vitro Activity of the Combination of Ceftazidime and Moxifloxacin

Sadic, Betul; Basaran, Seniha; Simsek-Yavuz, Serap; Cagatay, Atahan; Ozsut, Halit; Eraksoy, Haluk

doi:10.5152/kd.2019.08

Stenotrophomonas maltophilia: Results of Antimicrobial Susceptibility Testing and In Vitro Activity of the Combination of Ceftazidime and Moxifloxacin

Atıf İçin Kopyala

Sadic B., Basaran S., Simsek-Yavuz S., Cagatay A., Ozsut H., Eraksoy H.

KLIMIK JOURNAL, cilt.32, sa.1, ss.29-34, 2019 (ESCI)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 32 Sayı: 1
Basım Tarihi: 2019
Doi Numarası: 10.5152/kd.2019.08
Dergi Adı: KLIMIK JOURNAL
Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
Sayfa Sayıları: ss.29-34
İstanbul Üniversitesi Adresli: Evet

Özet

Objective: Recommended combination for the treatment of serious Stenotrophomonas maltophilia infections is ticarcillin-clavulanate and co-trimoxazole (SXT). However, first agent is not available in our country, and the second component may be a matter of antimicrobial resistance or intolerance. Therefore, we aimed to evaluate antimicrobial susceptibility testing results of S. maltophilia and in vitro activity of ceftazidime and moxifloxacin as a potential therapeutic alternative.